First-In Man (FIM) Study MR-Linac

NACompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

April 1, 2017

Primary Completion Date

July 11, 2017

Study Completion Date

September 8, 2017

Conditions
Bone Metastases
Interventions
DEVICE

Magnetic resonance imager linear accelerator

The MR linear accelerator (MRL) integrates a radiotherapy accelerator and a diagnostic quality 1.5T MRI, enabling soft-tissue visualization during the actual radiation delivery for improved targeting. This enables on-line treatment optimization for precise radiation delivery. Better visualization of the tumour targets and the surrounding healthy tissues, at the exact moment of treatment, makes it possible to adapt the dose to the actual anatomy while optimally sparing normal tissues.

Trial Locations (1)

3584 CX

University Medical Centre Utrecht, Utrecht

All Listed Sponsors
collaborator

Factory CRO for Medical Devices B.V.

OTHER

lead

Nucletron Operations BV

INDUSTRY

NCT03284619 - First-In Man (FIM) Study MR-Linac | Biotech Hunter | Biotech Hunter